Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Terry Chrisomalis
Investing Group Leader

Summary

  • Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively.
  • The global urothelial carcinoma market is expected to reach $6.82 billion in 2032.
  • It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.
  • Results from the phase 1 U.S. and European study, using CRB-701 for patients with mUC and cervical cancer, expected in Q1 of 2025.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Scientists working in the laboratory

sanjeri/E+ via Getty Images

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) recently reported positive data from its phase 1 study using CRB-701 for the treatment of patients with metastatic urothelial carcinoma [mUC] and cervical cancer. However, this was data that was reported

Please subscribe to my Seeking Alpha Marketplace Service "Biotech Analysis Central", whereby you can subscribe to either my "Full Tier" at $399/yr or my "Basic Tier" service at $299/yr instead. If you want to see what my articles are about you could also check out my "Free Tier" where you get a snippet of one of my 4 weekly ExclusiveBAC Articles, whereby I discuss biotechs in detail such as pipeline updates, catalysts, financials, and other information. Please do check out what I have to offer and see if my service is a right fit for you. 

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About CRBP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CRBP

Related Stocks

SymbolLast Price% Chg
CRBP
--
Compare

Trending Analysis

Trending News